Company Description
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Its lead product candidates are Revuforj, a menin inhibitor, which has completed phase 2 clinical trial for the treatment of relapsed or refractory and acute leukemia.
The company is revumenib for R/R mNPM1 AML and studying the use of revumenib in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia across the treatment landscape, including in newly diagnosed patients.
It also developing Niktimvo, a colony stimulating factor-1 receptor, blocking antibody, which is in phase 2 clinical trial for the treatment of chronic graft-versus-host disease.
The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat.
Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2005 |
| IPO Date | Mar 3, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 270 |
| CEO | Michael Metzger |
Contact Details
Address: 730 Third Avenue, 9th Floor New York, New York 10017 United States | |
| Phone | 781 419 1400 |
| Website | syndax.com |
Stock Details
| Ticker Symbol | SNDX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001395937 |
| CUSIP Number | 87164F105 |
| ISIN Number | US87164F1057 |
| Employer ID | 32-0162505 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael A. Metzger M.B.A. | Chief Executive Officer and Director |
| Dr. Neil Gallagher M.D., Ph.D. | President, Head of Research and Development |
| Keith Alan Goldan CPA | Chief Financial Officer, Treasurer and Chief Accounting Officer |
| Luke J. Albrecht J.D. | Senior Vice President, General Counsel and Secretary |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Richard A. Heyman Ph.D. | Co-Founder |
| Dr. Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board |
| Dr. Michael Downes Ph.D. | Co-Founder |
| Sharon Klahre | Vice President of Investor Relations and Communications |
| Kevin McManus | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 7, 2025 | SCHEDULE 13G/A | Filing |
| Mar 4, 2025 | 144 | Filing |
| Mar 4, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 3, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | SCHEDULE 13G | Filing |
| Feb 10, 2025 | 144 | Filing |
| Feb 10, 2025 | 144 | Filing |
| Feb 10, 2025 | 144 | Filing |